Abstract Background/Objectives The effectiveness of the BNT162b2 vaccine on preventing
the spread of COVID‐19 and deaths in nursing homes (NH) is unknown. Design We used …

Background: It is not known if widespread vaccination can prevent the spread of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in subpopulations at high risk, like …

Abstract Background/Objectives The safety and immunogenicity of the BNT162b2
coronavirus disease 2019 (COVID‐19) vaccine in older adults with different frailty and …

Background Duration of post‐vaccination protection against COVID‐19 in nursing home
(NH) residents is a critical issue. The objective of this study was to estimate the duration of …

Background There is incomplete information regarding evolution of antibody titers against
SARS‐CoV‐2 after a two‐dose strategy vaccination with BNT162b2 in older adults in long …

Introduction BNT162b2 (BioNTech and Pfizer) is a nucleoside-modified mRNA vaccine that
provides protection against SARS-CoV-2 infection and is generally well tolerated. However …

Objective To compare rates of incident SARS‐CoV‐2 infection and 30‐day hospitalization or
death among residents with confirmed infection in nursing homes with earlier versus later …

Introduction: In early 2020, the novel SARS-CoV-2 virus began to spread around the world
and claim victims. Initially, in the Western world, COVID-19-related mortality was due to …

Background After the first of three COVID‐19 vaccination clinics in US nursing homes (NHs),
the median vaccination coverage of staff was 37.5%, indicating the need to identify …

Objective To evaluate if facility-level vaccination after an initial vaccination clinic was
independently associated with COVID-19 incidence adjusted for other factors in January …